CClinicalTrials.gg
CompletedNCT05804292Valid-OBUpdated Apr 7, 2023

Psychometric Proprieties and Validation of Self-report Measures of Eating Behaviors

An observational study in Obesity and Eating Disorders, sponsored by Istituto Auxologico Italiano. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by Istituto Auxologico Italiano · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
300
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Obesity is a global epidemic and a major contributor to some of the leading causes of death.

Although research on overweight and obesity is constantly increasing, to date, in the Italian panorama, there is a lack of (A) rigorous psychological measurement tools of obesity-related constructs and (B) analysis of the relationships between constructs (and indicators) involved in the development and maintenance of overweight and obesity.

The present study aims to examine the psychometric properties of the main questionnaires for the assessment of eating behaviors in 3 groups of subjects (1) the general population (control group); (2) subjects with obesity without a comorbid diagnosis of an eating disorder; (3) subjects with obesity and a comorbid diagnosis of an eating disorder.

Read the detailed description

Participants were selected in the main rehabilitation centers for the treatment of obesity and eating disorders (sample of subjects with obesity) and through an online survey (community sample). The survey lasted about 30 minutes and - together with selected demographic and biomedical information - required the completion of the following self-report measures: the Binge Eating Scale (BES); the Modified Yale Food Addiction Scale version 2 (mYFAS 2.0); the Repetitive eating questionnaire (Rep-EAT); the Measure of Eating Compulsivity (MEC); the Addiction-like Eating Behavioural Scale (AEBS); the Three Factor Eating Questionnaire 18 (TFEQ-18); the Eating Disorders Examination Questionnaire-Short Form (EDEQ-SF); the Palatable Eating Motive Scale (PEMS); the Weight Sigma Questionnaire (WSSQ); the Emotional Eating Scale (EES); the Somatic Symptom Scale 8 (SSS8).

Before administration, all questionnaires were first translated from English (their original language) to Italian by two bilingual translators, independently - then back-translated into English by another independent translator whose mother tongue was English to ensure equivalence between the translations. Following, a purposive sample of respondents was asked to fill in the final version of each measure in order to assess its items' comprehensibility.

In order to avoid halo effects, the questionnaires were presented to the subject in random order.

The responders could withdraw the administration at any time, and contact a psychologist independent from the study in case of perceived emotional distress.

02

Conditions studied

  • Obesity
  • Eating Disorders
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,695 are open to participants now.

This study's enrollment of 300 is above the median of 135 across 1,283 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 196 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Subjects with obesity with/without an eating disorder AND the general population (non clinical)

Inclusion criteria

  • BMI > 30 kg/m2 (clinical sample)
  • Diagnosis of an eating disorder (clinical sample)
  • age range 18-75 years
  • Italian mother tongue
  • written and informed consent to participate

Exclusion criteria

Exclusion Criteria:

  • visual impairing
  • neurological problems
  • alcohol/drug abuse
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
300 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Community sample

    Questionnaires administration

    Other: Questionnaire administration

  • Subjects with obesity and comorbid eating disorder

    Questionnaires administration

    Other: Questionnaire administration

  • Subjects with obesity without comorbid eating disorder

    Questionnaires administration

    Other: Questionnaire administration

Interventions

  • OtherQuestionnaire administration

    Questionnaire administration

06

What researchers measure

Primary outcomes

  1. Binge Eating

    Score on the Binge Eating Scale. Each question has 3-4 separate responses assigned a numerical value. The score range is from 0-46: Non-binging; less than 17; Moderate binging; 18-26; Severe binging; 27 and greater

    Time frame: Baseline

  2. Food Addiction

    Scored on the Modified Yale Food Addiction Scale version 2 and at the Addiction-like Eating Behavioural Scale The "symptom count" score, ranging from 0 to 7, that reflects the number of addiction-like criteria endorsed was applied

    Time frame: Baseline

07

Study locations

1 site
  • Istituto Auxologico Italiano
    Milan, 20145, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05804292
Lead sponsor
Istituto Auxologico Italiano
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Mar 15, 2021
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022
Last update
Apr 7, 2023

Study contacts

Giada Pietrabissa, PhD
principal investigator · IRCCS Istituto Auxologico Italiano

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion